✨ Free AI Report
iTeos Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research iTeos Therapeutics, Inc.
Company Research

iTeos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for patients with cancer. The company has agreed to be acquired by Concentra Biosciences through a te...

Analyst-debate audio for iTeos Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for iTeos Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Pre-acquisition wind-down biotech with failed lead program and uncertain asset value...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Immuno-Oncology
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest iTeos Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

iTeos Therapeutics, Inc. Overview

Pro stress-test →

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for patients with cancer. The company has agreed to be acquired by Concentra Biosciences through a tender offer and merger, followed by delisting from Nasdaq. The company was advancing novel immunotherapy candidates targeting tumor immunosuppression but faced significant clinical setbacks.

Strategic Profile

Pro stress-test →

The company's lead candidate belrestotug is a TIGIT antagonist designed to activate immune cells, while its pipeline also includes inupadenant (A2AR antagonist), EOS-984 (ENT1 inhibitor), and EOS-215 (anti-TREM2 antibody). In 2025, iTeos announced a strategic shift, stating its intention to wind down operations and focus on maximizing shareholder value through its cash position and potential asset sales.

Competitive Landscape

Pro stress-test →

iTeos competes in the immuno-oncology therapeutic development space with other companies developing checkpoint inhibitors and immune-modulating therapies. Primary competitors include major pharma and clinical-stage biotech firms developing anti-TIGIT, A2AR antagonist, and other immunotherapy approaches for cancer. The competitive landscape features established players from GSK and other major pharma, making it challenging for independent clinical-stage companies.

Industry Context

iTeos Therapeutics, Inc. operates in Biopharmaceutical/Immuno-Oncology.

Key facts

Founded: 2010 · Headquarters: Watertown, Massachusetts, United States · Market cap: ~$389-449 million

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on iTeos Therapeutics, Inc..

  • Company agreed to acquisition by Concentra Biosciences at $10.047 per share plus contingent value rights
  • Lead candidate belrestotug + dostarlimab failed to meet clinical efficacy criteria in Phase 2 lung cancer trial
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2025Company entered definitive merger agreement with Concentra Biosciences for acquisition
  • March 2025Announced intention to cease operations and wind down business
  • +1 moreTrack every material event for iTeos Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when iTeos Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Anti-TIGIT antibodies and checkpoint inhibitorsPartners and competitors in immuno-oncology space→A2A receptor antagonistsCompeting immunotherapy modalities→

Compare iTeos Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

iTeos Therapeutics, Inc. operates in Biopharmaceutical/Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about iTeos Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare iTeos Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did iTeos Therapeutics, Inc. do this quarter?”
“Is iTeos Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does iTeos Therapeutics, Inc. do?+
iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for patients with cancer. The company has agreed to be acquired by Concentra Biosciences through a te...
What is iTeos Therapeutics, Inc.'s Cyborg Score?+
iTeos Therapeutics, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are iTeos Therapeutics, Inc.'s main competitors?+
Named competitors include Anti-TIGIT antibodies and checkpoint inhibitors, A2A receptor antagonists. The full competitive landscape is in the AskCyborg report.
How can I get the full iTeos Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the iTeos Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track iTeos Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score